- Home
- MYD vs EBS Comparison
MYD vs EBS Comparison
Compare MYD & EBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYD
- EBS
- Stock Information
- Founded
- MYD 1991
- EBS 1998
- Country
- MYD United States
- EBS United States
- Employees
- MYD N/A
- EBS N/A
- Industry
- MYD Investment Bankers/Brokers/Service
- EBS Biotechnology: Pharmaceutical Preparations
- Sector
- MYD Finance
- EBS Health Care
- Exchange
- MYD Nasdaq
- EBS Nasdaq
- Market Cap
- MYD 523.6M
- EBS 459.6M
- IPO Year
- MYD N/A
- EBS 2006
- Fundamental
- Price
- MYD $10.38
- EBS $8.09
- Analyst Decision
- MYD
- EBS Strong Buy
- Analyst Count
- MYD 0
- EBS 2
- Target Price
- MYD N/A
- EBS $14.00
- AVG Volume (30 Days)
- MYD 253.1K
- EBS 999.1K
- Earning Date
- MYD 01-01-0001
- EBS 11-06-2024
- Dividend Yield
- MYD 4.55%
- EBS N/A
- EPS Growth
- MYD N/A
- EBS N/A
- EPS
- MYD N/A
- EBS N/A
- Revenue
- MYD N/A
- EBS $1,125,500,000.00
- Revenue This Year
- MYD N/A
- EBS $6.64
- Revenue Next Year
- MYD N/A
- EBS $7.95
- P/E Ratio
- MYD N/A
- EBS N/A
- Revenue Growth
- MYD N/A
- EBS 2.05
- 52 Week Low
- MYD $8.76
- EBS $1.42
- 52 Week High
- MYD $11.30
- EBS $15.10
- Technical
- Relative Strength Index (RSI)
- MYD 19.14
- EBS 39.08
- Support Level
- MYD $11.16
- EBS $8.35
- Resistance Level
- MYD $11.44
- EBS $8.86
- Average True Range (ATR)
- MYD 0.14
- EBS 0.50
- MACD
- MYD -0.10
- EBS -0.11
- Stochastic Oscillator
- MYD 8.20
- EBS 17.58
About MYD Blackrock MuniYield Fund Inc.
Blackrock Muniyield Fund Inc is a non-diversified, closed-end management investment company. The fund's objective is to provide shareholders with as high a level of current income exempt from U.S. federal income taxes as is consistent with its investment policies and prudent investment management. The company invests in Transportation, Corporate, Health, Utilities, Education, Housing, and other sectors.
About EBS Emergent Biosolutions Inc.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company operates across three different segments, namely Commercial, Products, and Services. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.